

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/654.743	09/01/2000	Robert G. Korneluk	07891/003005

Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110 CONFIRMATION NO. 7148
ABANDONMENT/TERMINATION
LETTER

OC000000008748675*

Date Mailed: 09/09/2002

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 01/10/2002.

A petition to the Commissioner under 37 CFR 1.137 may be filed requesting that the application be revived.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(I); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL** DELAY must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Any questions concerning petitions to revive should be directed to "Office of Petitions" at (703) 305-9282.

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Instial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PROSECUTION	PATENT ATTORNE	EY DOCKET NUMBER:	27891/0	03005		
The U.S. PTO date stamp sets forth the date of receipt of:						
Applicant/Patentee:	ert G.	Korneluk e	tal.			
Serial/Patent Number:	9/654	743		······································		
	berly					
Title: MAMMALIA	N TAP	GENE FAMIL	TA Brin	nERS,		
PROBES, A			ETHODS			
 □ Notice of Missing Parts □ Reply to Missing Parts 	Pages: Pages:			Pages:		
☐ Reply to Examiner's Action				Pages:		
□ Extension of Time	Pages:	_ □ Preliminary Amendm		Pages:		
¬ □ Notice of Appeal	Pages:		1K U 7 2002 🕶	Pages:		
□ Appeal Brief	Pages:		للكر عدم	Number:		
□ Drawings Formal/Informal	Pages:		istim &	Pages: <u>38</u>		
□ M-Fee Payment	Pages:	Other Sea XI	SILM	rages. Oto		
□ Issue Fee Payment	Pages:	KOthe Con LOCNO	FICE TO COMP	Mages:		
□ Check	Ψ		12009	7 "355"		
Other Reply to No	stice to C	comply		Pages: 2		
Atty/Secy: (68) mHE/	ient/Matter Name	AEGERA TAB	-MIAP	Date: 3 4 05		
tm\$		ı	DIV.			







United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USDIO.GOV

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/654,743

09/01/2000

Robert G. Korneluk

07891/003005

CONFIRMATION NO. 7148

Date Mailed: 01/10/2002

FORMALITIES LETTER

OC000000007293659

Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

A statement that the contents of the paper and computer readable copies are the same and contain no new matter.

If there are any\charges, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: <u>March 1, 2002</u>

Kristina/Bieker-Brady, Ph/D.

Reg. No. 39,109

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\\Clark-w2k1\\documents\07891\07891.003005 Reply to Notice to Comply.wpd

21559

1 (881CB (1882) 1983) 2010) 671CD 1884 (1881



PATENT ATTORNEY DOCKET NO. 07891/003005

Certificate of Mailing: Date of Deposit: March 4, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as First class mail with sufficient postage on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202

TRACE / Comons

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert G. Korneluk et al.

Art Unit:

1643

Serial No.:

09/654,743

Examiner:

Not yet assigned

Filed:

September 1, 2000

Customer No.:

21559

Title:

MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES, AND

DETECTION METHODS

Box Sequence P.O. Box 2327 Arlington, VA 22202

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In reply to the Notice To Comply mailed January 10, 2002, Applicants submit the following:

- ☑ A substitute paper copy of the sequence listing and an amendment directing its entry into the specification.



PATENT ATTORNEY DOCKET NO. 07891/003005

Certificate of Mailing: Date of Deposit: 11200 2

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as First class mail with sufficient postage on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202

Printed name of person mailing correspondence

Printed name of person mailing correspondence S

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert G. Korneluk et al.

Art Unit:

1643

Serial No.:

09/654,743

Examiner:

Not yet assigned

Filed:

September 1, 2000

Customer No.:

21559

Title:

MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES, AND

DETECTION METHODS

Box Sequence P.O. Box 2327

Arlington, VA 22202

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed September 1, 2000, enclosed is a substitute sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 38 pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Murch 4, 1002

Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\\Clark-w2k1\documents\07891\07891.003005 Sequence Statemtment.wpd

21559

I MALIN THE THE STATE SHARE WERE COLD